Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma.


Journal

Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624

Informations de publication

Date de publication:
24 06 2022
Historique:
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 29 6 2022
Statut: ppublish

Résumé

Long-term senescent cells exhibit a secretome termed the senescence-associated secretory phenotype (SASP). Although the mechanisms of SASP factor induction have been intensively studied, the release mechanism and how SASP factors influence tumorigenesis in the biological context remain unclear. In this study, using a mouse model of obesity-induced hepatocellular carcinoma (HCC), we identified the release mechanism of SASP factors, which include interleukin-1β (IL-1β)- and IL-1β-dependent IL-33, from senescent hepatic stellate cells (HSCs) via gasdermin D (GSDMD) amino-terminal-mediated pore. We found that IL-33 was highly induced in senescent HSCs in an IL-1β-dependent manner in the tumor microenvironment. The release of both IL-33 and IL-1β was triggered by lipoteichoic acid (LTA), a cell wall component of gut microbiota that was transferred and accumulated in the liver tissue of high-fat diet-fed mice, and the release of these factors was mediated through cell membrane pores formed by the GSDMD amino terminus, which was cleaved by LTA-induced caspase-11. We demonstrated that IL-33 release from HSCs promoted HCC development via the activation of ST2-positive T

Identifiants

pubmed: 35749514
doi: 10.1126/sciimmunol.abl7209
doi:

Substances chimiques

GSDMD protein, human 0
Gsdmd protein, mouse 0
Interleukin-33 0
Phosphate-Binding Proteins 0
Pore Forming Cytotoxic Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabl7209

Auteurs

Ryota Yamagishi (R)

Department of Pathophysiology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).

Fumitaka Kamachi (F)

Department of Pathophysiology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).
Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan.

Masaru Nakamura (M)

Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan.

Shota Yamazaki (S)

Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan.

Tomonori Kamiya (T)

Department of Pathophysiology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).

Masaki Takasugi (M)

Department of Pathophysiology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).

Yi Cheng (Y)

Department of Pathophysiology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).

Yoshiki Nonaka (Y)

Department of Pathophysiology, Osaka City University, Graduate School of Medicine, Osaka, Japan.

Yoshimi Yukawa-Muto (Y)

Department of Pathophysiology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).
Department of Hepatology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).

Le Thi Thanh Thuy (LTT)

Department of Hepatology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).

Yohsuke Harada (Y)

Laboratory of Pharmaceutical Immunology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.

Tatsuya Arai (T)

Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan.

Tze Mun Loo (TM)

Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan.
Cancer Institute, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.

Shin Yoshimoto (S)

Cancer Institute, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.

Tatsuya Ando (T)

Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan.

Masahiro Nakajima (M)

Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan.

Hayao Taguchi (H)

Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan.

Takamasa Ishikawa (T)

Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.

Hisaya Akiba (H)

Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.

Sachiko Miyake (S)

Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.

Masato Kubo (M)

Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Noda, Chiba, Japan.
Laboratory for Cytokine Regulation, Research Center for Integrative Medical Science (IMS), RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan.

Yoichiro Iwakura (Y)

Center for Animal Disease Models, Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Chiba, Japan.

Shinji Fukuda (S)

Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
Gut Environmental Design Group, Kanagawa Institute of Industrial Science and Technology, Kawasaki, Kanagawa, Japan.
Transborder Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Wei-Yu Chen (WY)

Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Norifumi Kawada (N)

Department of Hepatology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).

Alexander Rudensky (A)

Howard Hughes Medical Institute and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Susumu Nakae (S)

Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima City, Hiroshima, Japan.
Precursory Research for Embryonic Science and Technology (PRESTO), Japan Science and Technology Agency, Saitama, Japan.

Eiji Hara (E)

Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka, Japan.
Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Japan.

Naoko Ohtani (N)

Department of Pathophysiology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan (formerly, Osaka City University).
Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba, Japan.
AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH